Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rezpegaldesleukin (NKTR-358) in Systemic Lupus Erythematosus
NCT03556007Phase 1Completed
- Sponsor
- Nektar Therapeutics
- Start
- Apr 2018
- Primary completion
- Aug 2019
- Modality
- Biologic, rProtein (Recombinant Protein), Polyethylene glycol conjugate
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of rezpegaldesleukin in systemic lupus erythematosus (SLE) (4 cohorts), sponsored by Nektar Therapeutics. Primary endpoint: Number of Participants Experiencing Adverse Events at Day 79. Started Apr 2018; status: completed.
02
Drugs
rezpegaldesleukin
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT03556007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03556007.